VILLEURBANNE, France–(BUSINESS WIRE)–Le spécialiste des lunettes de sécurité Bollé Safety propose désormais des verres correcteurs en Trivex. Un matériau hyper performant à la pointe de l’innovation, qui offre de très bonnes propriétés optiques et un…
Author: Business Wire
Tesseract Health Closes Oversubscribed $80 Million Series B Financing
GUILFORD, Conn.–(BUSINESS WIRE)–Tesseract Health Inc. has raised $80 million in an oversubscribed Series B financing round.
Protección ocular avanzada contra la covid-19 para los profesionales sanitarios – una tecnología de seguridad exclusiva de Bollé Safety
VILLEURBANNE, Francia–(BUSINESS WIRE)–Bollé Safety, líder mundial en el diseño y la fabricación de gafas de protección, ha presentado su división Healthcare dedicada a todos los profesionales sanitarios. Su gama de gafas de protección con tratamiento…
Innovativer Augenschutz gegen Covid-19 für medizinisches Fachpersonal — eine Technologie exklusiv von Bollé Safety
VILLEURBANNE, Frankreich–(BUSINESS WIRE)–Bollé Safety, einer der in der Entwicklung und Herstellung von Schutzbrillen weltweit führende Anbieter, stellt seinen Unternehmensbereich Healthcare vor, der sich an alle Fachkräfte im Gesundheitswesen richte…
Dirk Sauer, Ph.D. Joins Iconic Therapeutics' Board of Directors
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor (TF) biology to new therapeutics for cancer, retinal disease and inflammation…
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced…
Canva Partners with Donate Life America
SAN FRANCISCO–(BUSINESS WIRE)–Canva has partnered with Donate Life America, releasing a free collection of design templates for social media channels and marketing materials.
GenSight Biologics publie sa situation nette de trésorerie au 31 mars 2021 et fait un point sur ses activités
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le tr…
GenSight Biologics Reports Cash Position as of March 31, 2021 and Provides Operational Update
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Global Dry Eye Syndrome Market Report 2021: Market Reached a Value of $3.9 Billion in 2020 – Industry Trends, Share, Size, Growth, Opportunity and Forecast to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global dry eye syndrome market reached a value of US…
Adult Myopia Epidemiology Market Forecast Report 2018-2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Adult Myopia – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. This ‘Adult Myopia-Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the historical and for…
Inflammasome Therapeutics’ Kamuvudines May Be Answer to Preventing Blindness in Aging Population
NEWTON, Mass.–(BUSINESS WIRE)– #AMD–Inflammasome Therapeutics’ Kamuvudines may be answer to preventing blindness in aging population. Research published last week points to potential.
Fabrinet to Announce Third Quarter 2021 Financial Results on May 3, 2021
BANGKOK, Thailand–(BUSINESS WIRE)– #EarningsDate–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex pro…
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
Bollé Safety Now Offers Trivex Options for Its Prescription Safety Lenses
VILLEURBANNE, France–(BUSINESS WIRE)–Global eye protection specialist Bollé Safety now provides Trivex. A high-performance, high-technology prescription lens providing maximum security and great optical properties to ensure the best safety in a work …
Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics files registration statement for proposed initial public offering in the United States.
Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology
VILLEURBANNE, France–(BUSINESS WIRE)–Bollé Safety, world leader in the design and manufacture of protective eyewear, presents its new products dedicated to all healthcare professionals.
Global Glaucoma Surgery Devices Market to 2030 – Analysis and Forecast Model – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma Surgery Devices (Ophthalmic Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)” report has been added to ResearchAndMarkets.com’s offering. This report was built to visualize quantitativ…
New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.
New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.